CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease
Abstract: Both the incidence and prognosis of arterial atherothrombosis and venous thromboembolism are strongly correlated with increasing age. Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has been identified as a novel biomarker for cardiovascular disease. Driven by...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Blood Advances |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S247395292400661X |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832595745621934080 |
|---|---|
| author | Angela Todorovski Tzu-Fei Wang Marc Carrier Yan Xu |
| author_facet | Angela Todorovski Tzu-Fei Wang Marc Carrier Yan Xu |
| author_sort | Angela Todorovski |
| collection | DOAJ |
| description | Abstract: Both the incidence and prognosis of arterial atherothrombosis and venous thromboembolism are strongly correlated with increasing age. Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has been identified as a novel biomarker for cardiovascular disease. Driven by somatic mutations in the hematopoietic system, the epidemiology of CHIP is highly age dependent: among individuals aged ≥70 years in the general population, estimated prevalence of CHIP exceeds 10%. Several additional risk factors for CHIP have emerged in recent years, including smoking, receipt of anticancer therapy, and germ line predispositions. CHIP carriers consistently have higher risk of incident arterial atherothrombosis, even after accounting for traditional cardiovascular risk factors. However, the magnitude of this association varies across studies. In addition, individuals with established cardiovascular disease and CHIP have higher risks of recurrence and all-cause mortality than their non-CHIP counterparts. An association between CHIP carriership and incident venous thromboembolism has recently been made, although additional studies are needed to confirm this finding. No approved therapy exists to modify the cardiovascular risk among CHIP carriers. However, canakinumab showed promise in a post-hoc analyses of patients with TET2-mutated CHIP, and other anti-inflammasome agents are actively under development or evaluation. In this review, we provide an overview of CHIP as a mediator of thromboembolic diseases and discuss emerging therapeutics aimed at intervening on this thrombo-inflammatory nexus. |
| format | Article |
| id | doaj-art-3675cfc86df24cb38ff96253c9c2f3a0 |
| institution | Kabale University |
| issn | 2473-9529 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Blood Advances |
| spelling | doaj-art-3675cfc86df24cb38ff96253c9c2f3a02025-01-18T05:04:59ZengElsevierBlood Advances2473-95292025-01-0192343353CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic diseaseAngela Todorovski0Tzu-Fei Wang1Marc Carrier2Yan Xu3Department of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, CanadaDepartment of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, CanadaDepartment of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, CanadaDepartment of Medicine, University of Ottawa and Ottawa Hospital Research Institute, Ottawa, ON, Canada; School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada; Correspondence: Yan Xu, Department of Medicine, University of Ottawa and The Ottawa Hospital, Box 201a, 501 Smyth Rd, Ottawa, ON, K1H 8L6, Canada;Abstract: Both the incidence and prognosis of arterial atherothrombosis and venous thromboembolism are strongly correlated with increasing age. Over the past decade, clonal hematopoiesis of indeterminate potential (CHIP) has been identified as a novel biomarker for cardiovascular disease. Driven by somatic mutations in the hematopoietic system, the epidemiology of CHIP is highly age dependent: among individuals aged ≥70 years in the general population, estimated prevalence of CHIP exceeds 10%. Several additional risk factors for CHIP have emerged in recent years, including smoking, receipt of anticancer therapy, and germ line predispositions. CHIP carriers consistently have higher risk of incident arterial atherothrombosis, even after accounting for traditional cardiovascular risk factors. However, the magnitude of this association varies across studies. In addition, individuals with established cardiovascular disease and CHIP have higher risks of recurrence and all-cause mortality than their non-CHIP counterparts. An association between CHIP carriership and incident venous thromboembolism has recently been made, although additional studies are needed to confirm this finding. No approved therapy exists to modify the cardiovascular risk among CHIP carriers. However, canakinumab showed promise in a post-hoc analyses of patients with TET2-mutated CHIP, and other anti-inflammasome agents are actively under development or evaluation. In this review, we provide an overview of CHIP as a mediator of thromboembolic diseases and discuss emerging therapeutics aimed at intervening on this thrombo-inflammatory nexus.http://www.sciencedirect.com/science/article/pii/S247395292400661X |
| spellingShingle | Angela Todorovski Tzu-Fei Wang Marc Carrier Yan Xu CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease Blood Advances |
| title | CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease |
| title_full | CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease |
| title_fullStr | CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease |
| title_full_unstemmed | CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease |
| title_short | CHIP away at the marrow-clot connection: inflammation, clonal hematopoiesis, and thromboembolic disease |
| title_sort | chip away at the marrow clot connection inflammation clonal hematopoiesis and thromboembolic disease |
| url | http://www.sciencedirect.com/science/article/pii/S247395292400661X |
| work_keys_str_mv | AT angelatodorovski chipawayatthemarrowclotconnectioninflammationclonalhematopoiesisandthromboembolicdisease AT tzufeiwang chipawayatthemarrowclotconnectioninflammationclonalhematopoiesisandthromboembolicdisease AT marccarrier chipawayatthemarrowclotconnectioninflammationclonalhematopoiesisandthromboembolicdisease AT yanxu chipawayatthemarrowclotconnectioninflammationclonalhematopoiesisandthromboembolicdisease |